There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zogenix (ZGNX) and Atara Biotherapeutics (ATRA) with bullish sentiments.
Zogenix (ZGNX)
Mizuho Securities analyst Difei Yang reiterated a Buy rating on Zogenix today and set a price target of $55.00. The company’s shares closed last Monday at $23.10, close to its 52-week low of $16.65.
According to TipRanks.com, Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.1% and a 32.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Revance Therapeutics, and Sarepta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zogenix with a $40.00 average price target.
See today’s analyst top recommended stocks >>
Atara Biotherapeutics (ATRA)
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Atara Biotherapeutics, with a price target of $38.00. The company’s shares closed last Monday at $14.40.
According to TipRanks.com, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.2% and a 43.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology, Coherus Biosciences, and Wave Life Sciences.
Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $58.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATRA:
